"I also often add that this review process has been going on longer than anticipated. But given that our technology is a first-in-class and innovative cell therapy that the MHRA has never seen before it appears they are being extra careful in their review. I conclude that given our active engagement with them, every day that passes is a day closer to their decision."
There you have it. Nothing special, nothing extra, just the MHRA being extra careful. Don't read more into it than that.